Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

IOVA | Iovance Biotherapeutics Inc

Index	RUT	P/E	-	EPS (ttm)	-2.25	Insider Own	19.33%	Shs Outstand	247.78M	Perf Week	-22.93%
Market Cap	1.13B	Forward P/E	-	EPS next Y	-1.43	Insider Trans	11.68%	Shs Float	199.89M	Perf Month	-24.84%
Income	-418.83M	PEG	-	EPS next Q	-0.45	Inst Own	73.97%	Short Float / Ratio	15.04% / 4.88	Perf Quarter	-39.31%
Sales	0.24M	P/S	4718.14	EPS this Y	24.47%	Inst Trans	-2.04%	Short Interest	30.07M	Perf Half Y	-17.36%
Book/sh	2.57	P/B	1.77	EPS next Y	24.09%	ROA	-61.23%	Target Price	24.55	Perf Year	-54.53%
Cash/sh	1.01	P/C	4.51	EPS next 5Y	-	ROE	-79.68%	52W Range	4.41 - 10.41	Perf YTD	-28.48%
Dividend	-	P/FCF	-	EPS past 5Y	-11.99%	ROI	-64.59%	52W High	-56.10%	Beta	0.14
Dividend %	-	Quick Ratio	2.99	Sales past 5Y	0.00%	Gross Margin	-10221.01%	52W Low	3.63%	ATR	0.47
Employees	503	Current Ratio	3.10	Sales Q/Q	-	Oper. Margin	-179988.66%	RSI (14)	33.02	Volatility	7.76% 7.47%
Optionable	Yes	Debt/Eq	0.14	EPS Q/Q	24.87%	Profit Margin	-175981.09%	Rel Volume	1.75	Prev Close	4.87
Shortable	Yes	LT Debt/Eq	0.12	Earnings	Aug 08 AMC	Payout	-	Avg Volume	6.16M	Price	4.57
Recom	1.31	SMA20	-20.09%	SMA50	-30.38%	SMA200	-33.61%	Volume	10,772,562	Change	-6.16%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-23	Reiterated	Barclays	Overweight	$40 → $18
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$11 → $17
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$11
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight	$11 → $14
Dec-09-22	Downgrade	Goldman	Buy → Neutral	$20 → $6
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight	$14
Jan-28-22	Upgrade	Stifel	Hold → Buy	$23 → $25
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$32
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral	$35 → $18
May-19-21	Downgrade	Stifel	Buy → Hold
May-19-21	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-03-21	Initiated	Truist	Buy	$50
Apr-16-21	Initiated	Goldman	Buy	$97
Mar-08-21	Upgrade	H.C. Wainwright	Neutral → Buy	$50
Dec-15-20	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-06-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-22-20	Initiated	Mizuho	Buy	$61
Mar-04-20	Initiated	Barclays	Overweight	$45

Show Previous Ratings

Sep-22-23 06:25PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-15-23 04:20PM	Why Iovance Biotherapeutics Stock Rocketed 13% Higher Today (Motley Fool) +13.46%
07:26AM	Iovance (IOVA) Up Despite FDA's Delayed Decision on Melanoma Drug (Zacks)
Sep-14-23 06:10PM	U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma (GlobeNewswire) -14.54%
04:36PM	Why Shares of Iovance Biotherapeutics Dropped Thursday (Motley Fool)
11:30AM	Loading…
Sep-07-23 11:30AM	Why Is Iovance Biotherapeutics (IOVA) Down 21.2% Since Last Earnings Report? (Zacks)
07:31AM	Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-31-23 10:16PM	12 Best High Risk High Reward Stocks To Buy Now (Insider Monkey)
Aug-28-23 11:53PM	3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List (InvestorPlace)
Aug-18-23 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-09-23 11:14AM	Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2 (Zacks) +6.44%
Aug-08-23 05:50PM	Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:50PM	Iovance Biotherapeutics: Q2 Earnings Snapshot (AP Finance)
04:01PM	Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates (GlobeNewswire)
Jul-31-23 06:10AM	7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick (InvestorPlace)
04:01PM	Loading…
Jul-25-23 04:01PM	Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer (GlobeNewswire)
Jul-24-23 04:01PM	Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023 (GlobeNewswire)
Jul-21-23 05:34PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-13-23 04:01PM	Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering (GlobeNewswire)
Jul-11-23 04:30PM	These Stocks Are Moving the Most Today: Activision, Amazon, WD-40, Affirm, Shutterstock, and More (Barrons.com) -9.78%
11:18AM	Why Iovance Biotherapeutics Stock Is Dropping Tuesday (Motley Fool)
10:53AM	Iovance (IOVA) Gets Positive FDA Feedback on Lung Cancer Drug (Zacks)
09:26AM	Why These 2 Nasdaq Biotech Stocks Fell Hard Tuesday Morning (Motley Fool)
04:56AM	Iovance Biotherapeutics slips after $150 million stock offering price announced (Investing.com)
Jul-10-23 09:46PM	Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock (GlobeNewswire) +21.41%
04:34PM	Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
07:00AM	Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer (GlobeNewswire)
Jun-24-23 03:19PM	11 Best Medical Stocks Under $10 (Insider Monkey)
Jun-20-23 07:01AM	Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape (GlobeNewswire)
Jun-16-23 08:39AM	Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study (Zacks) -6.02%
07:01AM	Loading…
Jun-15-23 07:01AM	Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma (GlobeNewswire)
Jun-09-23 07:01AM	Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
Jun-08-23 11:30AM	Why Is Iovance Biotherapeutics (IOVA) Up 7.9% Since Last Earnings Report? (Zacks)
May-30-23 04:18PM	Why Shares of Iovance Biotherapeutics Jumped Tuesday (Motley Fool) +17.22%
04:18PM	These Stocks Moved the Most Today: Nvidia, Marvell, C3.ai, Palantir, and More (Barrons.com)
01:54PM	These Stocks Are Moving the Most Today: Nvidia, Marvell, C3.ai, Palantir, and More (Barrons.com)
May-29-23 10:08AM	FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug (Zacks)
May-26-23 05:30PM	Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma (GlobeNewswire)
May-24-23 12:03PM	A US$352m Market Cap Boost Pleasing ToIovance Biotherapeutics Insiders \ (Simply Wall St.) -10.93%
May-16-23 09:25AM	Billionaire Steve Cohen Snaps Up These 2 Strong Buy Stocks Heres Why You Might Want to Ride His Coattails (TipRanks)
May-11-23 01:40PM	Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-10-23 12:16PM	Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q1 (Zacks)
May-09-23 04:01PM	Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
May-02-23 04:01PM	Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023 (GlobeNewswire)
May-01-23 04:00PM	Why Shares of Iovance Biotherapeutics Jumped Monday (Motley Fool) +14.01%
Apr-24-23 07:01AM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
Apr-20-23 09:45AM	Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon (Motley Fool)
Apr-06-23 07:22AM	Should You Hold Iovance Biotherapeutics (IOVA)? (Insider Monkey)
Mar-30-23 11:30AM	Why Is Iovance Biotherapeutics (IOVA) Down 9.2% Since Last Earnings Report? (Zacks) -7.24%
Mar-27-23 03:56PM	Why Shares of Iovance Biotherapeutics Jumped Monday (Motley Fool) +11.21%
11:35AM	Iovance (IOVA) Completes Rolling BLA Filing for Melanoma Drug (Zacks)
Mar-24-23 04:01PM	Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma (GlobeNewswire)
Mar-21-23 05:10PM	12 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-04-23 08:13AM	Great week for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) institutional investors after losing 43% over the previous year (Simply Wall St.)
Mar-02-23 09:17PM	Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-01-23 12:33PM	Q4 2022 Iovance Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
11:04AM	Iovance (IOVA) Q4 Earnings In Line With Estimates, Revenues Nil (Zacks)
08:03AM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
Feb-28-23 04:01PM	Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates (GlobeNewswire)
Feb-27-23 09:31AM	Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More (Zacks)
Feb-21-23 04:01PM	Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023 (GlobeNewswire)
Jan-24-23 12:15PM	Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6% (Zacks) +9.86%
Jan-23-23 06:37PM	Why Iovance Biotherapeutics Stock Soared 12% Higher Today (Motley Fool) +11.64%
11:39AM	Iovance Biotherapeutics Acquires Clinigen's IL-2 Product For Upfront £166.7M (Benzinga)
08:00AM	Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates (GlobeNewswire)
Dec-16-22 09:54AM	12 Stocks Insiders are Buying Now (Insider Monkey)
Dec-11-22 07:23AM	Trade Alert: The Independent Director Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), Wayne Rothbaum, Has Just Spent US$65m Buying 124% More Shares (Simply Wall St.)
Nov-30-22 07:00AM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
Nov-21-22 12:11PM	Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug (Zacks)
Nov-18-22 01:06PM	Why Iovance Biotherapeutics Is Crashing Today (Motley Fool) -6.76%
12:09PM	Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate (Benzinga)
09:00AM	Iovance's stock is down after receiving FDA feedback on application for new melanoma drug (MarketWatch)
06:30AM	Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma (GlobeNewswire)
Nov-12-22 08:34AM	Bullish insiders at Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) loaded up on US$6.9m of stock earlier this year (Simply Wall St.)
Nov-10-22 12:33PM	Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) +10.59%
Nov-07-22 08:01AM	Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) -7.75%
Nov-04-22 12:31PM	Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil (Zacks)
Nov-03-22 04:01PM	Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates (GlobeNewswire)
Oct-27-22 07:19PM	11 Best Very Cheap Stocks To Buy Now According To Hedge Funds (Insider Monkey)
Oct-24-22 04:01PM	Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022 (GlobeNewswire)
Oct-11-22 11:49AM	Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study (Zacks)
Oct-10-22 07:30AM	Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy (GlobeNewswire) -11.46%
Oct-05-22 09:45AM	Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy (Zacks)
08:05AM	Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Sep-12-22 07:00AM	Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer (GlobeNewswire)
Sep-06-22 04:01PM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire) -8.74%
09:00AM	Iovance Biotherapeutics to Present Posters at ESMO 2022 (GlobeNewswire)
Aug-26-22 01:13PM	Iovance (IOVA) Starts Rolling BLA With FDA for Melanoma Therapy (Zacks) -5.90%
Aug-25-22 01:05PM	Biomedical technician training program launches to support Philadelphia's growing life sciences sector (American City Business Journals)
07:30AM	Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma (GlobeNewswire)
Aug-05-22 12:13PM	Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track (Zacks)
Aug-04-22 04:01PM	Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates (GlobeNewswire)
Jul-27-22 07:00AM	Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022 (GlobeNewswire)
Jul-22-22 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.91%
Jun-22-22 10:48AM	Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs (Zacks) +7.29%
Jun-17-22 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.75%
Jun-13-22 04:01PM	Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors (GlobeNewswire) -7.47%
Jun-12-22 09:00AM	Five Beaten-Up Biotech Stocks Saw Big Share Purchases (Barrons.com)
Jun-08-22 04:01PM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire) +9.86%
Jun-06-22 08:34PM	Down More Than 40%: Insiders Call a Bottom in These 2 Stocks (TipRanks)

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCPEAK MERRILL A	Director	Sep 18	Buy	5.56	10,000	55,600	248,633	Sep 19 04:30 PM
Rothbaum Wayne P.	Director	Sep 15	Buy	5.30	5,000,000	26,500,000	23,067,333	Sep 15 06:12 PM
BILINSKY IGOR	Chief Operating Officer	Jul 14	Option Exercise	0.00	2,813	0	28,608	Jul 17 06:21 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jul 14	Option Exercise	0.00	2,813	0	32,348	Jul 17 06:22 PM
Vogt Frederick G	Interim CEO & General Counsel	Jul 14	Option Exercise	0.00	20,834	0	81,701	Jul 17 06:22 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Apr 14	Option Exercise	0.00	2,812	0	30,930	Apr 18 05:49 PM
Vogt Frederick G	Interim CEO & General Counsel	Apr 14	Option Exercise	0.00	20,834	0	69,718	Apr 18 05:50 PM
BILINSKY IGOR	Chief Operating Officer	Apr 14	Option Exercise	0.00	2,812	0	27,190	Apr 18 05:48 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jan 17	Option Exercise	0.00	11,248	0	32,796	Jan 19 04:52 PM
BILINSKY IGOR	Chief Operating Officer	Jan 17	Option Exercise	0.00	11,248	0	29,049	Jan 19 04:52 PM
Vogt Frederick G	Interim CEO & General Counsel	Jan 17	Option Exercise	0.00	83,325	0	85,325	Jan 19 04:51 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jan 03	Option Exercise	0.00	19,690	0	32,571	Jan 05 08:57 PM
BILINSKY IGOR	Chief Operating Officer	Jan 03	Option Exercise	0.00	18,850	0	28,354	Jan 05 08:45 PM
Bellemin Jean-Marc	Chief Financial Officer	Jan 03	Option Exercise	0.00	18,850	0	28,354	Jan 05 08:45 PM
MCPEAK MERRILL A	Director	Dec 21	Buy	6.15	10,000	61,500	70,150	Dec 22 04:06 PM
Rothbaum Wayne P.	Director	Dec 02	Buy	6.50	10,000,000	65,000,000	18,067,333	Dec 02 05:29 PM
MCPEAK MERRILL A	Director	Nov 29	Buy	6.31	10,000	63,100	238,633	Nov 30 04:17 PM
MCPEAK MERRILL A	Director	Nov 28	Buy	6.18	10,000	61,800	228,633	Nov 28 09:44 PM
Vogt Frederick G	Interim CEO & General Counsel	Nov 28	Buy	5.98	1,000	5,980	2,000	Nov 28 09:46 PM
Dukes Iain D.	Director	Nov 23	Buy	6.10	10,000	61,000	22,000	Nov 28 09:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IOVA | Iovance Biotherapeutics Inc

Upgrade your FINVIZ experience